Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Decline Accept
Home › Insider trades › Regeneron Pharmaceuticals › Officer exercised or converted 14K REGN derivative securities Insider trades
Why it stands out Derivative exercise or conversion — not an open-market buy.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
All the details
Dates, kept separate
Transaction date Nov 20, 2025
Reporting period Not applicable
Filed with the SEC Nov 24, 2025 Officer Option exercise
Context Classification option exercise
Code M — exercise or conversion of a derivative security
Planned / mechanical clue Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
Record ID 0001238303-25-000005
Filed / recorded
Nov 24, 2025, 9:07 PM UTC
Added to OQRO Oct 2, 2026, 12:28 PM UTC
Data quality Verified: identifiers matched exactly
Issuer REGENERON PHARMACEUTICALS, INC.
Reporting person Joseph J Larosa
Officer title EVP General Counsel and Secret
Security Non-Qualified Stock Option (right to buy)
Table Derivative (Table II)
Transaction date Nov 20, 2025
Acquired / disposed Disposed (D)
Footnotes from the filing The stock option award vested in four equal annual installments, commencing one year after the date of grant.
Around the same time Congress
Traded Nov 18, 2025 · disclosed 27 days later
2 different filers disclosed REGN within 90 days.
Insider filing
Traded Dec 9, 2025 · filed 2 days later
Routine share withholding; mechanical by default.
Insider filing
Traded Dec 9, 2025 · filed 2 days later
Routine share withholding; mechanical by default.
The story around this disclosure Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
Sep 25, 2025 FDA FDA drug approval: Evkeeza Oct 6, 2025 Company filing · Form 8-K · Results Reported its results Oct 8, 2025 FDA FDA drug approval: Libtayo Oct 9, 2025 FDA FDA drug approval: Praluent Oct 28, 2025 Company filing · Form 8-K · Results Reported its results Oct 29, 2025 FDA FDA drug approval: Libtayo Oct 29, 2025 Insider · 1 person Insiders: 6 sales (~$4.3M) Nov 7, 2025 Insider Officer sold ~$281K of REGN shares in the open market Nov 18, 2025 Congress Disclosed purchase of REGN — reported range $1,001 - $15,000 Nov 19, 2025 FDA FDA drug approval: Eylea HD Nov 20, 2025 Insider Director sold ~$570K of REGN shares in the open market What came next Jan 7, 2026 Insider Director sold ~$1.2M of REGN shares in the open market Jan 12, 2026 Company filing · Form 8-K · Results, Reg FD Reported its results, and shared information with investors Jan 30, 2026 Company filing · Form 8-K · Results Reported its results Feb 9, 2026 Insider · 2 people
Insiders: 24 sales (~$1.7M)